
IvÃ;n HenrÃ-quez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8508101/publications.pdf Version: 2024-02-01



ΙνΔ:Ν ΗΕΝΡΔΟΠΕΖ

#	Article	IF	CITATIONS
1	Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease. World Journal of Clinical Oncology, 2021, 12, 6-12.	0.9	3
2	Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). Biomedicines, 2021, 9, 1247.	1.4	22
3	Clinical Applications of Molecular Biomarkers in Prostate Cancer. Cancers, 2020, 12, 1550.	1.7	21
4	Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR). Clinical and Translational Oncology, 2020, 22, 1378-1389.	1.2	11
5	Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy. Radiotherapy and Oncology, 2019, 141, 156-163.	0.3	19
6	Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes. Clinical and Translational Oncology, 2019, 21, 1044-1051.	1.2	6
7	Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology. Clinical and Translational Oncology, 2019, 21, 420-432.	1.2	6
8	Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG. Clinical and Translational Oncology, 2018, 20, 392-401.	1.2	1
9	Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy. Reports of Practical Oncology and Radiotherapy, 2017, 22, 251-257.	0.3	3
10	The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort. Clinical and Translational Oncology, 2016, 18, 1026-1033.	1.2	2
11	Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. Journal of Neuro-Oncology, 2016, 127, 569-579.	1.4	40
12	Hypofractionated high-dose-rate plesiotherapy in nonmelanoma skin cancer treatment. Brachytherapy, 2015, 14, 859-865.	0.2	41
13	Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy. Strahlentherapie Und Onkologie, 2015, 191, 792-800.	1.0	1
14	Quality assurance in radiotherapy: analysis of the causes of not starting or early radiotherapy withdrawal. Radiation Oncology, 2014, 9, 260.	1.2	19
15	Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity. Radiation Oncology, 2014, 9, 102.	1.2	49
16	Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. Neuro-Oncology, 2013, 15, 797-805.	0.6	77
17	Exeresis and Brachytherapy as Salvage Treatment for Local Recurrence After Conservative Treatment for Breast Cancer: Results of a Ten-Year Pilot Study. International Journal of Radiation Oncology Biology Physics, 2010, 78, 804-810.	0.4	66
18	Cosmetic outcome of breast conservative treatment for early stage breast cancer. Clinical and Translational Oncology, 2006, 8, 334-338.	1.2	29

#	Article	IF	CITATIONS
19	Treatment of keloids by high-dose-rate brachytherapy: A seven-year study. International Journal of Radiation Oncology Biology Physics, 2001, 50, 167-172.	0.4	152
20	Symptom prevalence in the last week of life. Journal of Pain and Symptom Management, 1997, 14, 328-331.	0.6	158
21	Intraoperative and external beam radiotherapy in advanced resectable gastric cancer: Technical description and preliminary results. International Journal of Radiation Oncology Biology Physics, 1989, 17, 183-189.	0.4	24
22	Postoperative radical radiotherapy with concurrent weekly intra-arterial cis-platinum for treatment of malignant glioma: a pilot study. Radiotherapy and Oncology, 1989, 14, 83-88.	0.3	16